<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03604614</url>
  </required_header>
  <id_info>
    <org_study_id>GDPHCM-GI-03</org_study_id>
    <nct_id>NCT03604614</nct_id>
  </id_info>
  <brief_title>Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer With Peritoneal Metastatis</brief_title>
  <official_title>A Randomized Controlled Clinical Trial of Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer With Peritoneal Metastatis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Provincial Hospital of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong Provincial Hospital of Traditional Chinese Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The incidence rate of gastric cancer is high in Southeast Asia, so is the mortality rate.Due
      to the lack of specific performance, about 5%-20% of patients have found peritoneal
      metastases at the time of first diagnosis.At present, clinical studies on HIPEC in the
      treatment of patients with advanced gastric cancer peritoneal metastasis are almost related
      to abdominal perfusion after laparoscopic gastrectomy.Herein, we conduct a single-centre
      randomized controlled trial to explore the safety and feasibility of laparoscopic exploration
      combined with HIPEC in the treatment of advanced gastric cancer with peritoneal metastasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastric cancer is one of the most common digestive tumors in the world.In China, advanced
      gastric cancer with severe local progression or distant metastasis is more common.Gastric
      cancer with peritoneal carcinomatosis has an extremely poor prognosis,with a median survival
      of less than 6 months.Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is currently a
      treatment for malignant tumors in the abdominal cavity and prevents tumor recurrence and
      metastasis.Studies have shown that hyperthermic intraperitoneal perfusion chemotherapy
      (HIPEC) has good clinical efficacy in the prevention and treatment of peritoneal metastasis
      of gastric cancer and its associated malignant ascites.Therefore,we conduct a single-centre
      randomized controlled trial to explore the safety and feasibility of HIPEC in the treatment
      of advanced gastric cancer with peritoneal metastasis. The metahnism of HIPEC is taking
      advantage of the difference in temperature sensitivity between cancer cells and normal cells.
      Perfusion of the abdominal cavity with a chemical fluid of the appropriate temperature can be
      performed. Suitable high temperatures can directly kill tumor cells.It is generally believed
      that the optimal temperature for the treatment of tumors is 42.5°C to 44°C.In this study,we
      set the temperature 43°C. Paclitaxel is a novel broad-spectrum antitumor drug,which has a
      unique anti-cancer mechanism.We use Paclitaxel as peritoneal hyperthermic perfusion
      chemotherapy drugs.The chemotherapy is SOX(Teggio and Oxaliplatin),.The primary endpoint is
      PFS. Secondary endpoints are one-year OS、canversion rate and ascites assessment. A phase III
      study PHOENIX-GC trial had finished enrollment,and the conclusion was the median OS 17.7 and
      15.2 months respectively for IP and SP.The primary analysis did not show the statistical
      superiority of the IP regimen.The sensitivity analysis IP considering the imbalance of
      ascites, suggested clinical efficacy of IP PTX in gastric cancer with peritoneal metastasis.
      For this reason,we conduct a trial to explore the safety and feasibility of HIPEC in the
      treatment of advanced gastric cancer with peritoneal metastasis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Anticipated">August 24, 2020</completion_date>
  <primary_completion_date type="Actual">August 24, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death for tumor cause, whichever came first, assessed 7 months</time_frame>
    <description>Progression-free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1-year survival</measure>
    <time_frame>one year</time_frame>
    <description>1-year overall survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ascites assessment</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Ascites assessment during surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median survival</measure>
    <time_frame>From date of randomization until only 50% of individuals living for tumor cause, assessed 2 years</time_frame>
    <description>Median Survival Time</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Stage IV Gastric Cancer With Metastasis</condition>
  <condition>Hyperthermic Intraperitoneal Chemotherapy</condition>
  <condition>Exploratory Behavior</condition>
  <arm_group>
    <arm_group_label>HIPEC and chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperthermic Intraperitoneal Chemotherapy and SOX（Tiggio+Oxaliplatin ）</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Without HIPEC</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Without Hyperthermic Intraperitoneal Chemotherapy，Only SOX（Tiggio+Oxaliplatin ）</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperthermic Intraperitoneal Chemotherapy</intervention_name>
    <description>The investigators use Paclitaxel as peritoneal hyperthermic perfusion chemotherapy drugs，75mg/m2 for the first time，50mg/m2 for the second time and third time.The chemotherapy is SOX(Tiggio d1-d14 bid po and Oxaliplatin 130mg/m2 ivd d1 qd).The Tiggio dosage depends on the patient's body surface area, body surface area &lt;1.25m2 40mg/time, 1.25-1.50m2 50mg/time, &gt;1.50m2 60mg/time.</description>
    <arm_group_label>HIPEC and chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Without Hyperthermic Intraperitoneal Chemotherapy</intervention_name>
    <description>The chemotherapy is SOX(Tiggio d1-d14 bid po and Oxaliplatin 130mg/m2 ivd d1 qd).The Tiggio dosage depends on the patient's body surface area, body surface area &lt;1.25m2 40mg/time, 1.25-1.50m2 50mg/time, &gt;1.50m2 60mg/time.</description>
    <arm_group_label>Without HIPEC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary gastric adenocarcinoma diagnosed pathologically by endoscopic biopsy；

          -  Laparoscopic exploration of patients with advanced gastric adenocarcinoma of
             peritoneal metastasis；

          -  Eastern Cooperative Oncology Group (ECOG): 0 ot 1；

          -  American Society of Anesthesiologists （ASA） score: I to Ⅲ；

          -  Patient informed consent。

        Exclusion Criteria:

          -  Pregnancy or female in suckling period；

          -  Severe mental illness；

          -  Preoperative imaging or intraoperative exploration reveals distant blood, liver, lung,
             and brain metastases；

          -  5 years of history of other malignant diseases；

          -  A history of unstable angina or myocardial infarction within 6 months；

          -  History of cerebral infarction or cerebral hemorrhage within 6 months；

          -  A history of sustained systemic corticosteroid treatment within 1 month；

          -  Emergency operation due to complication (bleeding, perforation or obstruction) caused
             by primary tumor；

          -  Pulmonary function test FEV1 &lt;predicted value 50%。
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong Provincial Hospital of Traditional Chinese Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wenjun Xiong</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong Provincial Hospital of Traditional Chinese Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wei Wang, M.D., PH.D.</last_name>
    <phone>+86-13922255515</phone>
    <email>wangwei16400@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guangdong Province Hospital of Chinese Medicine, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Wang, M.D.,PH.D.</last_name>
      <phone>+86-13922255515</phone>
      <email>wangwei16400@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Wenjun Xiong, M.D.</last_name>
      <phone>+86-15920553177</phone>
      <email>xiongwj1988@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Wei Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jin Wan</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wen jun Xiong</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>De chang Diao</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yan sheng Zheng</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hong ming Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yao bin He</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Li jie Luo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 14, 2018</study_first_submitted>
  <study_first_submitted_qc>July 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2018</study_first_posted>
  <last_update_submitted>July 20, 2018</last_update_submitted>
  <last_update_submitted_qc>July 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangdong Provincial Hospital of Traditional Chinese Medicine</investigator_affiliation>
    <investigator_full_name>Wei Wang</investigator_full_name>
    <investigator_title>Wei Wang M.D., PhD.，Head of Gastroenterology, Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>peritoneal metastatis</keyword>
  <keyword>Hyperthermic Intraperitoneal Chemotherapy</keyword>
  <keyword>Advanced gastric adenocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The data has not been published.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

